Pathophysiology of Dupuytren's Contracture
| ISRCTN | ISRCTN88164211 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN88164211 |
| Secondary identifying numbers | 6585 |
- Submission date
- 11/08/2010
- Registration date
- 11/08/2010
- Last edited
- 18/04/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Liaquat Suleman-Verjee
Scientific
Scientific
Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
W6 8LH
United Kingdom
Study information
| Study design | Multicentre non-randomised interventional treatment trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | GP practice |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Pathophysiology of Dupuytren's Contracture |
| Study objectives | Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types. |
| Ethics approval(s) | MREC approved, ref: 06/Q0403/95 |
| Health condition(s) or problem(s) studied | Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery |
| Intervention | Elucidate the exact role of tenascin-C in Dupuytren's disease |
| Intervention type | Other |
| Primary outcome measure | Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 02/11/2006 |
| Completion date | 31/07/2011 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Planned sample size: 90 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 02/11/2006 |
| Date of final enrolment | 31/07/2011 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Imperial College London
London
W6 8LH
United Kingdom
W6 8LH
United Kingdom
Sponsor information
Royal College of Surgeons of England (UK)
University/education
University/education
35-43 Lincoln's Inn Fields
London
WC2A 3PE
England
United Kingdom
| Website | http://www.rcseng.ac.uk/ |
|---|---|
"ROR" |
https://ror.org/02qrg5a24 |
Funders
Funder type
Charity
Healing Foundation
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
18/04/2017: No publications found, verifying study status with principal investigator.
